ASTS
AST SpaceMobile, Inc.
ASTS has a slight edge over AVNW overall, supported by stronger fundamentals and stronger modeled upside.
AVNW
Aviat Networks, Inc.
AVNW has lower modeled downside risk, despite its lower overall score.
ASTS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
ASTS's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
AVNW Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Stable | |
| Healthy |
AVNW's balance sheet is currently healthy, and its revenue and cash flow are stable, but its profitability is under pressure.
ASTS PE Valuation
ASTS has no meaningful PE right now: it lost money over the past year.
AVNW PE Valuation
AVNW has no meaningful PE right now: it lost money over the past year.
ASTS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect ASTS's losses to grow, with revenue growing. However, they disagree widely on these estimates.
AVNW Forward outlook
There aren't enough analyst estimates for AVNW to show an outlook.
ASTS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.15 | -$0.91 |
| Q2 2026 | -$2.16 | -$0.27 |
| Q1 2026 | -$1.80 | +$0.19 |
| Q4 2025 | -$1.34 | +$0.61 |
| Q3 2025 | -$1.24 | +$0.88 |
| Q2 2025 | -$1.89 | -$0.64 |
| Q1 2025 | -$1.99 | -$1.01 |
| Q4 2022 | -$0.58 | -$0.21 |
ASTS is still losing money, but far less than before: $2.15 per share over the past year, against $5.76 at its worst in mid-2021.
AVNW Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.04 | -104% |
| Q2 2026 | $0.19 | +90% |
| Q1 2026 | $0.71 | +$1.02 |
| Q4 2025 | $1.14 | +$1.45 |
| Q3 2025 | $1.05 | +$1.47 |
| Q2 2025 | $0.10 | -88% |
| Q1 2025 | -$0.31 | -127% |
| Q4 2024 | -$0.31 | -124% |
AVNW has the edge over ASTS on earnings, with more consistent year-over-year improvement.
ASTS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $42.3M | +187% |
| Q2 2026 | $31.5M | +2627% |
| Q1 2026 | $14.7M | +1952% |
| Q4 2025 | $54.3M | +2731% |
| Q3 2025 | $14.7M | +1240% |
| Q2 2025 | $1.2M | +28% |
| Q1 2025 | $718K | +44% |
| Q3 2022 | $4.2M | +70% |
ASTS has the edge over AVNW on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -415% | +694 points |
| Q2 2026 | -948% | +10744 points |
| Q1 2026 | -1686% | +7083 points |
| Q4 2025 | -175% | +2446 points |
| Q3 2025 | -1109% | +4850 points |
| Q2 2025 | -11692% | -4693 points |
| Q1 2025 | -8769% | +2331 points |
| Q4 2024 | -2621% | N/A |
ASTS's operating margin was −415% last quarter, up 694 points from the same quarter a year ago.
AVNW Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $102M | -5% |
| Q2 2026 | $120.9M | +4.8% |
| Q1 2026 | $100M | -11% |
| Q4 2025 | $111.5M | -5.7% |
| Q3 2025 | $107.3M | +21% |
| Q2 2025 | $115.3M | +1.3% |
| Q1 2025 | $112.6M | +0.9% |
| Q4 2024 | $118.2M | +24% |
AVNW's revenue is shrinking: $102M last quarter, down 5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 0.9% | -4 points |
| Q2 2026 | 4.8% | -2.9 points |
| Q1 2026 | 0.9% | -7.3 points |
| Q4 2025 | 6.5% | -0.2 points |
| Q3 2025 | 4.8% | +22 points |
| Q2 2025 | 7.7% | +4.3 points |
| Q1 2025 | 8.3% | +3.8 points |
| Q4 2024 | 6.7% | +1.5 points |
AVNW has the edge over ASTS on profitability, with a higher operating margin.
ASTS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$464.2M | -$161.4M |
| Q2 2026 | -$694.8M | -$341.1M |
| Q1 2026 | -$309.7M | -$160.7M |
| Q4 2025 | -$330.7M | -$220.3M |
| Q3 2025 | -$302.9M | -$239.1M |
| Q2 2025 | -$353.6M | -$315.3M |
| Q1 2025 | -$149M | -$61.3M |
| Q4 2024 | -$110.5M | -$63.2M |
ASTS has burned cash in almost every quarter: −$1.8B over the past year, against −$916M the year before.
AVNW Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$7.2M | +$6.3M |
| Q2 2026 | $2.5M | -70% |
| Q1 2026 | -$5.4M | -$4.2M |
| Q4 2025 | $22.5M | +23% |
| Q3 2025 | -$13.5M | +$19.1M |
| Q2 2025 | $8.2M | +9.9% |
| Q1 2025 | -$1.2M | -108% |
| Q4 2024 | $18.3M | +$26M |
AVNW has the edge over ASTS on cash generation, producing positive trailing cash flow while its opponent burns cash.
ASTS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +1.1M shares |
| 1 year | +10% | +27.3M shares |
| 3 years | +235% | +211M shares |
| 5 years | +480% | +248M shares |
| Available history | +944% | +271M shares |
ASTS has 300M diluted shares, up 10% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
AVNW Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.6% | -205K shares |
| 1 year | -1.2% | -154K shares |
| 3 years | +7.4% | +879K shares |
| 5 years | +7.3% | +868K shares |
| Available history | +18% | +2M shares |
AVNW has the edge over ASTS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $75,000 |
| Q1 2026 | $500,000 |
| Q1 2024 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | $4.6M |
| Q1 2022 | $2M |
ASTS Net Leverage
ASTS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
AVNW Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.6x | Healthy |
| Q2 2026 | 1.1x | Healthy |
| Q1 2026 | 1.0x | Healthy |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 1.2x | Healthy |
| Q2 2025 | 1.8x | Healthy |
| Q1 2025 | 2.4x | Moderate |
| Q4 2024 | 3.7x | Elevated |
AVNW's net debt is about 1.6 years of its operating earnings (EBITDA), up from 1.2 years a year ago.
ASTS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.1 | Neutral |
| Stochastic | 11.9 | Oversold |
ASTS's weekly RSI is 34 (neutral) and its Stochastic is 12 (oversold).
AVNW Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.8 | Neutral |
| Stochastic | 19.1 | Oversold |
AVNW's weekly RSI is 37 (neutral) and its Stochastic is 19 (oversold).
ASTS PE vs Technology Sector
ASTS has no meaningful PE right now: it lost money over the past year.
AVNW PE vs Technology Sector
| Metric | AVNW | Sector median | Relative |
|---|---|---|---|
| PE | 93x | 28x | 234% above |
| PE % | 91 | 35 | 56 pts above |
AVNW has no meaningful PE right now: it lost money over the past year.
ASTS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $44.9 | 23% below |
| 20 week MA | $57.1 | 40% below |
| 50 week MA | $75.5 | 54% below |
| 100 week MA | $57.8 | 40% below |
| 200 week MA | $33.6 | 2.8% above |
ASTS has the edge over AVNW on trend strength, trading above more of its moving averages.
AVNW Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $19.3 | 12% below |
| 20 week MA | $20.2 | 16% below |
| 50 week MA | $21.0 | 20% below |
| 100 week MA | $21.1 | 20% below |
| 200 week MA | $25.5 | 34% below |
AVNW is in a downtrend: it's below all five of its weekly moving averages, and 34% below its 200-week average.
ASTS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.87 | $13.4 | +36% |
| 2021 | $13.4 | $8.71 | -35% |
| 2022 | $8.71 | $3.97 | -54% |
| 2023 | $3.97 | $6.03 | +52% |
| 2024 | $6.03 | $22.9 | +280% |
| 2025 | $22.9 | $72.0 | +214% |
| 2026 YTD | $72.0 | $34.5 | -52% |
ASTS's yearly returns have swung widely, from +280% in 2024 to −54% in 2022. It's down 52% so far in 2026.
AVNW Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $7.06 | $17.6 | +149% |
| 2021 | $17.6 | $31.7 | +80% |
| 2022 | $31.7 | $31.1 | -1.8% |
| 2023 | $31.1 | $32.7 | +5% |
| 2024 | $32.7 | $17.8 | -45% |
| 2025 | $17.8 | $21.4 | +20% |
| 2026 YTD | $21.4 | $16.9 | -21% |
AVNW has the edge over ASTS on returns for 2026, with the stronger performance.